Callodine Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-115,000
| Closed | -$6.67M | – | 39 |
|
|
2023
Q3 | $6.67M | Sell |
115,000
-5,000
| -4% | -$290K | 1.86% | 26 |
|
|
2023
Q2 | $7.67M | Buy |
120,000
+35,000
| +41% | +$2.24M | 2.2% | 16 |
|
|
2023
Q1 | $5.89M | Buy |
85,000
+5,000
| +6% | +$347K | 1.74% | 21 |
|
|
2022
Q4 | $5.76M | Sell |
80,000
-85,000
| -52% | -$6.12M | 1.71% | 21 |
|
|
2022
Q3 | $11.7M | Buy |
165,000
+92,500
| +128% | +$6.58M | 3.65% | 11 |
|
|
2022
Q2 | $5.58M | Sell |
72,500
-182,500
| -72% | -$14.1M | 1.65% | 25 |
|
|
2022
Q1 | $18.6M | Sell |
255,000
-15,000
| -6% | -$1.1M | 5.98% | 1 |
|
|
2021
Q4 | $16.8M | Sell |
270,000
-30,000
| -10% | -$1.87M | 6.53% | 1 |
|
|
2021
Q3 | $17.8M | Buy |
300,000
+22,500
| +8% | +$1.33M | 6.69% | 1 |
|
|
2021
Q2 | $18.5M | Buy |
277,500
+15,000
| +6% | +$1M | 7% | 2 |
|
|
2021
Q1 | $16.6M | Buy |
262,500
+62,500
| +31% | +$3.95M | 7.19% | 2 |
|
|
2020
Q4 | $12.4M | Buy |
200,000
+30,625
| +18% | +$1.9M | 6% | 3 |
|
|
2020
Q3 | $10.2M | Sell |
169,375
-20,625
| -11% | -$1.24M | 5.44% | 5 |
|
|
2020
Q2 | $11.2M | Sell |
190,000
-205,000
| -52% | -$12.1M | 5.48% | 7 |
|
|
2020
Q1 | $22M | Buy |
395,000
+85,000
| +27% | +$4.74M | 8.96% | 3 |
|
|
2019
Q4 | $19.9M | Buy |
310,000
+40,000
| +15% | +$2.57M | 7.88% | 5 |
|
|
2019
Q3 | $13.7M | Buy |
270,000
+210,000
| +350% | +$10.6M | 5.48% | 6 |
|
|
2019
Q2 | $2.72M | Buy |
+60,000
| New | +$2.72M | 1.19% | 23 |
|